

Group	Mice ID #	Spleen (termination)				Termination		HIV gag p24+CD3+CD8- T cell (%)		cART
		CD45 ^a	CD3 ^b	CD4 ^c	CD8 ^c	Plasma HIV VL (copies/ml)	WPI	spleen	Bone marrow	
MOCK	1304	66	40	66	26	ND ^d	12	0	0.03	Naive
MOCK	1305	63	72	60	30	ND ^d	12	0.03	0.08	Naive
MOCK	1451	59	28	71	23	ND ^d	13	0.07	0.02	Naive
MOCK	1452	77	51	63	32	ND ^d	13	0	0.06	Naive
MOCK	1454	34	17	76	16	ND ^d	13	0	0.01	Naive
MOCK	1809	55	43	72	21	ND ^d	15	0	0	Naive
MOCK	1810	46	58	69	25	ND ^d	15	0	0	Naive
JRCSF+PBS	1300	37	61	34	58	221800	12	1.2	6.17	Naive
JRCSF+PBS	1301	45	59	53	30	199803	12	3.8	2.27	Naive
JRCSF+PBS	1302	27	52	59	35	158183	12	2.96	1.99	Naive
JRCSF+PBS	1447	32	38	56	36	501187	13	1.76	1.17	Naive
JRCSF+PBS	1448	42	17	39	48	251188	13	2.5	7.91	Naive
JRCSF+PBS	1449	38	13	55	35	630957	13	4.57	7.4	Naive
JRCSF+PBS	1801	26	33	36	45	118051	15	6.6	6.29	Naive
JRCSF+PBS	1802	22	21	35	48	791237	15	3.11	4.31	Naive
JRCSF+PBS	1803	29	37	51	44	201236	15	4.28	5.5	Naive
JRCSF+cART+PBS	1306	18	48	65	27	ND ^d	12	0	0.01	PI+NNRTI+INTI
JRCSF+cART+PBS	1307	25	41	50	43	ND ^d	12	0.09	0.1	PI+NNRTI+INTI
JRCSF+cART+PBS	1308	69	38	60	35	ND ^d	12	0.02	0.07	PI+NNRTI+INTI
JRCSF+cART+PBS	1331	34	32	50	43	ND ^d	12	0.06	0.05	PI+NNRTI+INTI
JRCSF+cART+PBS	1332	64	43	56	33	ND ^d	13	0.05	0.09	PI+NNRTI+INTI
JRCSF+cART+PBS	1333	70	49	57	39	ND ^d	13	0	0.08	PI+NNRTI+INTI
JRCSF+cART+PBS	1459	65	58	64	22	ND ^d	12	0.08	0	PI+NNRTI+INTI
JRCSF+cART+PBS	1460	54	39	41	50	ND ^d	12	0	0.01	PI+NNRTI+INTI
JRCSF+cART+PBS	1461	68	77	74	18	ND ^d	13	0.02	0	PI+NNRTI+INTI
JRCSF+cART+PBS	1465	26	49	65	25	ND ^d	13	0	0.02	PI+NNRTI+INTI
JRCSF+cART+PBS	1467	42	76	56	35	ND ^d	13	0	0.01	PI+NNRTI+INTI
JRCSF+cART+PBS	1806	39	52	66	28	ND ^d	15	0.01	0	PI+NNRTI+INTI
JRCSF+cART+PBS	1807	42	48	70	25	ND ^d	15	0	0	PI+NNRTI+INTI
JRCSF+cART+PBS	1808	44	51	62	30	ND ^d	15	0.05	0.006	PI+NNRTI+INTI
JRCSF+cART+ONTAK	1309	58	42	63	32	657	12	0.44	0.33	PI+NNRTI+INTI
JRCSF+cART+ONTAK	1310	63	42	61	30	1260	12	0.53	0.43	PI+NNRTI+INTI
JRCSF+cART+ONTAK	1311	75	44	61	33	1542	12	0.37	0.16	PI+NNRTI+INTI
JRCSF+cART+ONTAK	1314	35	56	60	35	1805	12	0.27	0.16	PI+NNRTI+INTI
JRCSF+cART+ONTAK	1315	74	38	52	43	ND ^d	13	0.2	0.25	PI+NNRTI+INTI
JRCSF+cART+ONTAK	1316	34	36	61	29	ND ^d	13	0	0	PI+NNRTI+INTI
JRCSF+cART+ONTAK	1450	67	45	72	21	1383	12	0.23	0.2	PI+NNRTI+INTI
JRCSF+cART+ONTAK	1458	49	55	57	37	1280	12	0.36	0.31	PI+NNRTI+INTI
JRCSF+cART+ONTAK	1462	51	43	60	31	ND ^d	13	0	0	PI+NNRTI+INTI
JRCSF+cART+ONTAK	1463	37	50	64	34	ND ^d	13	0.02	0.02	PI+NNRTI+INTI
JRCSF+cART+ONTAK	1464	42	76	56	35	ND ^d	13	0	0.01	PI+NNRTI+INTI
JRCSF+cART+ONTAK	1466	52	69	65	30	ND ^d	13	0	0.03	PI+NNRTI+INTI
JRCSF+cART+ONTAK	1811	46	56	64	31	ND ^d	15	0	0.02	PI+NNRTI+INTI
JRCSF+cART+ONTAK	1812	41	59	68	27	ND ^d	15	0.02	0.04	PI+NNRTI+INTI
JRCSF+cART+ONTAK	1815	52	60	67	26	ND ^d	15	0.06	0.05	PI+NNRTI+INTI

a Percentage of human CD45+ of total cell.

b Percentage of CD3+ from human CD45+ cells.

c Percentage of CD4+ CD8+ from human CD45+CD3+ cells.

d ND; not detected.

Supplementary Table 1. Humanized mice with suppressed HIV-1 infection under cART treatment and mice with rebounded viral load after ONTAK treatment.